Method for preparing medicinal recombinant human interleukin-11

A technology for interleukin and fusion protein, which is applied in the field of preparation of pharmaceutical recombinant human interleukin-11, can solve the problems of uncontrollable degree of glycosylation, poor process stability, high process difficulty, etc., and achieves safety and effectiveness Sexual guarantee, quality controllable, good repeatability
CN101892279AInactive Publication Date: 2010-11-24XIAMEN AMOYTOP BIOTECH
4 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Current Assignee / Owner
XIAMEN AMOYTOP BIOTECH
Publication Date
2010-11-24
Estimated Expiration
Not applicable Β· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a method for preparing medicinal recombinant human interleukin-11, which adopts the following preparation steps of: 1) initial purification of a fusion protein in the interleukin-11, which comprises steps of crushing thalli and separating a chelate column; 2) digesting the fusion protein containing the interleukin-11 by enterokinase; and 3) fine purification of the interleukin-11, wherein Macro Cap SP column chromatography and Superdex-75 column chromatography are carried out to obtain the medicinal recombinant human interleukin-11. The method has the characteristics of simple process, high expression amount, high stability, uniform product, low production cost, environmental protection and high activity, improves the safety, controllability and validity of medicaments and is suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a preparation method of medicinal recombinant human interleukin-11. Belongs to the field of biotechnology. Background technique

[0002] Human interleukin-11 (IL-11) is a cytokine that exists in various tissues such as human bone marrow, nerves, respiratory tract and digestive tract epithelium, and has a wide range of physiological functions, especially its effect on the hematopoietic system. have important clinical value. Currently, recombinant human IL-11 ( Genetics Institute) was officially approved by the FDA in November 1997. Its indication is chemotherapy-induced thrombocytopenia, and it has become the only drug of choice for the treatment of chemotherapy-induced thrombocytopenia.

[0003] IL-11 was only discovered in the late 1980s. It was found that the culture medium derived from the bone marrow stromal cell line PU-34 could stimulate the growth of the T1165 cell line neutralized by excess IL-6 antibody. In 1990, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More